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Abstract
Background: Availability of accurate diagnostic tests has been helpful in curtailing the spread of
HIV infection. Among these, simple, point of care, inexpensive tests which require only a drop of
blood from finger-prick and give reliable results within minutes are a must for expansion of testing
services and for reaching mobile and marginalised populations. Such tests will not only be a boon
for the infrastructure-starved developing and underdeveloped countries but will also be extremely
useful in developed countries where post-testing compliance is a major problem. Our laboratory
has been involved in developing reagents for heamagglutination-based rapid detection of antibodies
to HIV in whole blood using recombinant molecules specific for either HIV-1 or HIV-2. Since it is
not required of a screening test to differentially detect HIV and HIV-2, it would useful to create a
single molecule capable of simultaneous detection of both HIV-1 and HIV-2 in a drop of blood.
Results: The present paper describes designing, high-level expression and large-scale purification
of new molecules comprising recombinant anti-RBC Fab fused to immunodominant regions of
envelope sequences from both gp41 of HIV-1 and gp36 of HIV-2. These immunodominant regions
of HIV envelope contain cysteine residues, which make disulfide bond and can interfere with the
assembly of light chain and heavy chain fragment to make Fab molecule in vitro. To circumvent this
problem, a series of fusion proteins having different combinations of native and mutant envelope
sequences were constructed, purified and evaluated for their efficacy in detecting antibodies to
HIV-1 and HIV-2. A chimeric molecule comprising native envelope sequence of gp41 of HIV-1 and
modified envelope sequence of gp36 of HIV-2 gave good production yield and also detected both
HIV-1 and HIV-2 samples with high sensitivity and specificity.
Conclusion: The new bifunctional antibody fusion protein identified in this study detects both
HIV-1 and HIV-2 infected samples efficiently and can be used in place of molecules that detect only
HIV-1 or HIV-2. This will make reagent production more economical as only one molecule has to
be produced in place of two molecules. Also, it will simplify the testing procedure allowing
detection of both HIV-1 and HIV-2 infections in a single drop of blood.
Background
The AIDS pandemic has already resulted in the death of
approximately 21.8 million people worldwide [1] and
this number will continue to increase at an alarming rate
until corrective measures are taken. Although the major
route of transmission is sexual contact, use of contami-
Published: 22 September 2006
BMC Biotechnology 2006, 6:39 doi:10.1186/1472-6750-6-39
Received: 20 June 2006
Accepted: 22 September 2006
This article is available from: http://www.biomedcentral.com/1472-6750/6/39
© 2006 Gupta and Chaudhary; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Biotechnology 2006, 6:39 http://www.biomedcentral.com/1472-6750/6/39
Page 2 of 12
(page number not for citation purposes)
nated blood and blood products is estimated to have
resulted in about 10% of all HIV infections worldwide.
Availability of accurate diagnostic tests can certainly help
in curtailing spread due to blood products. There has been
an explosion in diagnostic technologies in recent times
and simple, rapid, inexpensive tests, which require no
instrument and can be performed in any remote area pref-
erably with a drop of blood are the need of the hour. Such
type of tests will not only be a boon for the developing
and under-developed countries where infrastructure is
poor and resources are limited, but will also be extremely
helpful in developed countries in clinical settings such as
emergency rooms where obtaining immediate results
could be beneficial. In current practice, it takes between
24 hours to two weeks to get the test results because the
testing is conducted primarily in batches at centralized
testing laboratories. Delay in availability of test report
results in poor compliance in collection of the report and
post-test counseling; consequently large number of HIV
positive persons unaware of their HIV status, move
around in the society [2]. Rapid detection can significantly
decrease HIV transmission if these individuals are
informed and counseled immediately [3]. Rapid tests will
also be useful in immediate identification of pregnant
mothers at risk of having HIV infection who could be
given antiviral therapy during labor to reduce the inci-
dence of HIV transmission to newborn.
Our laboratory has been involved in development of
highly sensitive and specific reagents for detection of anti-
bodies to HIV in blood of infected individuals [4]. These
reagents consist of recombinant, monovalent, Fab-based
bifunctional antibody molecules having capacity to bind
to human RBC on one end and to anti-HIV antibodies
(which are present in the blood of HIV infected individu-
als and are bivalent) on the other end. The reaction leads
to cross linking of RBC in the blood of an HIV infected
person upon addition of the above-mentioned bifunc-
tional molecule. The cross-linking of RBC is seen as
clumping or agglutination of RBCs by naked eyes. On the
other hand, there is no cross-linking, if blood from a nor-
mal individual is used. The high level production of these
antibody fragments and their derivatives involves
cytosolic expression as inclusion bodies followed by
denaturation and in vitro renaturation procedure [5].
Earlier, we have described reagents consisting of Fab
fusion proteins, each carrying a single antigen derived
either from HIV-1 or from HIV-2, for the differential
detection of antibodies to HIV-1 and HIV-2 in a haemag-
glutination based assay [6]. However, for screening pur-
poses it is not important to differentially detect HIV-1 and
HIV-2 antibodies in a sample. Therefore, a single reagent
capable of detecting both anti HIV-1 and anti HIV-2 anti-
bodies simultaneously would simplify the testing process
and make it a one step test. This can be achieved by mixing
HIV-1 specific reagent and HIV-2 specific reagent before
adding to the test blood (our unpublished result). How-
ever, Fab fusion proteins carrying both antigens on the
same Fab molecule would be a better solution as it will
reduce the number of molecules required to be purified,
thereby simplifying the process of reagent production and
usage.
The development of a single molecule containing both
HIV-1 and HIV-2 specific immunodominant regions is
not straightforward. Both env1 and env2 sequences of
HIV contain disulfide bonds, which might interfere with
the in vitro assembly of LC and Fd chains to form Fab as
well as with correct disulfide bond formation within env1
and env2. This can be avoided by using a derivative of
envelope antigens carrying serine residues in place of
cysteine residues. However, absence of the disulfide bond
in the antigen may cause alteration in its reactivity with
antibodies present in serum samples from HIV-infected
patients [7]. In the present paper, we describe designing,
high level expression in E. coli, and purification of anti-
RBC Fab fusion proteins containing immunodominant
regions of both HIV-1 gp41 and HIV-2 gp36, and use of
these proteins for successful detection of both HIV-1 and
HIV-2 infected individuals, with high sensitivity and spe-
cificity.
Results
Vector for expression of various proteins
pVCB6Fd (Fig. 1A) carries sequence encoding amino acids
1–219 of the heavy chain (Fd; consisting of VH and CH1)
of an anti-RBC monoclonal antibody, B6, as Nhe I-Mlu I
insert. Nhe I site in the vector is preceded by Nde I site
(CATATG) whose ATG constitutes the initiation codon.
Mlu  I site that is used for cloning various envelope
sequences is followed by sequence for a ten amino acid
tag, cmyc that is recognised by MAb, 9E10 (Fig. 1A).
pVCB6LC1140 is similar to pVCB6Fd and carries
sequence encoding the light chain (amino acids 1–219) of
B6 as Nhe I-Mlu I insert (Fig. 1B). This plasmid contains a
stop codon after the coding sequence of B6LC and preced-
ing  Mlu  I site. In pVCB6Fdenv1C, following Fd, a
sequence encoding 31 amino acids (590–620) of HIV-1
gp41 (env1C) has been inserted (Fig. 1C; Table 1). This
plasmid expresses a fusion protein B6Fdenv1C (Fig. 2). In
pVCB6Fdenv2C, following Fd, a sequence encoding 31
amino acids (581–611) of HIV-2 gp36 (env2C) has been
inserted (Fig. 1C; Table 1). This plasmid expresses a fusion
protein B6Fdenv2C (Fig. 2). pVCB6Fdenv1S is similar to
pVCB6Fdenv1C but expresses a fusion protein,
B6Fdenv1S, with cysteine 605 and 611 residues present in
native gp41 replaced by serine residues. pVCB6Fdenv2S is
similar to pVCB6Fdenv2C but expresses a fusion protein,BMC Biotechnology 2006, 6:39 http://www.biomedcentral.com/1472-6750/6/39
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Diagrammatic representation of various plasmids encoding LC, Fd, and Fd fusion proteins Figure 1
Diagrammatic representation of various plasmids encoding LC, Fd, and Fd fusion proteins. All the plasmids carry insert 
between Nhe I (GCTAGC) and Mlu I (ACGCGT) restriction sites and are under the control of T7 promoter. ATG of Nde I 
site (CATATG) is the initiation codon. Only relevant genes and restriction sites are shown. The map is not to the scale. T7, T7 
promoter; env1C, 31 amino acids (590–620) of HIV-1 envelope gp41 containing native cysteine residues; env1S, 31 amino acids 
(590–620) of HIV-1 envelope gp41 with cysteine 605 and 611 replaced by serine residues; env2C, 31 amino acids (581–611) of 
HIV-2 envelope gp36 containing native cysteine residues; env2S, 31 amino acids (581–611) of HIV-2 envelope gp36 with 
cysteine 597 and 603 replaced by serine residues; cmyc, decapeptide recognized by monoclonal antibody, 9E10; T, T7 tran-
scription terminator; F+, phage M13 origin of replication; Ampr, β-lactamase gene; Ori, ColE1 origin of replication; VH, variable 
domain of the heavy chain of MAb B6; CH1, the first constant domain of heavy chain of B6; VL, variable domain of the light chain 
of B6; CL, constant domain of light chain of B6. A. Expression vector for B6Fd. B. Expression vector for B6LC. C. Segment of 
expression vector pVCB6Fdenv showing the cassette between B6Fd and cmyc. The cysteine residues in env1/env2, which make 
intra-molecular disulfide bond, are shown. The serine residues that replace the cysteine residues in env are shown. D. Segment 
of expression vector pVCB6Fdenv12 showing the cassette of chimeric env1 and env2 sequence between B6Fd and cmyc. The 
serine and cysteine residues in env sequences are shown. L, linker.
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Table 1: Alignment of amino acid sequence of envelope region of various single and double antigen fusion proteins.
Protein AMINO ACID SEQUENCES OF HIV-1 and HIV-2 ANTIGENS FUSED AT THE C-TERMINUS OF Fd
Fd------- -------ENV1S/C-------------LINKER L-----------------ENV2S/C----------------cmyc
Fd NASG
Fdenv1S NASGVERYLKDQQLLGIWGSSGKLISTTAVPWNAS----------------------------------------------EQKLISEEDLN
Fdenv1C NASGVERYLKDQQLLGIWGCSGKLICTTAVPWNAS----------------------------------------------EQKLISEEDLN
Fdenv2S NASG------------------------------------------ AIEKYLQDQARLNSWGSAFRQVSHTTVPWVNGASEQKLISEEDLN
Fdenv2C NASG------------------------------------------ AIEKYLQDQARLNSWGCAFRQVCHTTVPWVNGASEQKLISEEDLN
Fdenv12SS NASGVERYLKDQQLLGIWGSSGKLISTTAVPWSNASGGGSGGGASGAIEKYLQDQARLNSWGSAFRQVSHTTVPWVNGASEQKLISEEDLN
Fdenv12CC NASGVERYLKDQQLLGIWGCSGKLICTTAVPWSNASGGGSGGGASGAIEKYLQDQARLNSWGCAFRQVCHTTVPWVNGASEQKLISEEDLN
Fdenv12CS NASGVERYLKDQQLLGIWGCSGKLICTTAVPWSNASGGGSGGGASGAIEKYLQDQARLNSWGSAFRQVSHTTVPWVNGASEQKLISEEDLN
Fdenv12SC NASGVERYLKDQQLLGIWGSSGKLISTTAVPWSNASGGGSGGGASGAIEKYLQDQARLNSWGCAFRQVCHTTVPWVNGASEQKLISEEDLN
Amino acids are shown in single letter code with Serine (S) and Cysteine (C) in bold letters. The linker is shown in bold letters. Various proteins are shown diagrammatically in Fig. 2.BMC Biotechnology 2006, 6:39 http://www.biomedcentral.com/1472-6750/6/39
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B6Fdenv2S (Fig. 2), with cysteine 597 and 603 residues
present in native gp36 replaced by serine residues.
pVCB6Fdenv12SS (Fig. 1D) expresses a fusion protein
B6Fdenv12SS containing Fd of B6 antibody fused at its C-
terminus to sequences encoding amino acids 590 to 620
of gp41 with cysteine 605 and cysteine 611 replaced by
serine residues, an eleven amino acid linker (SGGGSG-
GGASG), amino acids 581 to 611 of gp36 with cysteine
597 and cysteine 603 replaced by serine residues and a
decapeptide tag, cmyc (Table 1). pVCB6Fdenv12CS,
pVCB6Fdenv12SC and pVCB6Fdenv12CC (Fig. 1D),
express fusion protein similar to B6Fdenv12SS with
cysteine in env1 (B6Fdenv12CS) or env2 (B6Fdenv12SC)
or both (B6Fdenv12CC) (Fig. 2, Table 1).
Expression of various proteins and preparation of inclusion 
bodies
BL21(λDE3) cells transformed with various plasmids
were grown and expression of the desired protein was
induced with IPTG. Cells from induced cultures were ana-
lysed for expression by SDS-PAGE under reducing condi-
tions. The expressed proteins corresponded to the
calculated molecular weight of the respective proteins.
Large-scale expression for all the constructs was done at
30°C. The expressed proteins constituted ~15–30% of
total cellular protein and the inclusion bodies purified
from this cell pellet constituted ~70–80% of total cellular
protein (data not shown).
Assembly of Fab molecules
For the assembly of various B6Fab derivatives, a protocol
comprising of in vitro denaturation of Fd/Fdenv and LC,
and their subsequent renaturation and association was
optimised. B6Fd derivatives and B6LC were completely
denatured and reduced and then mixed in equimolar
ratio. The assembly of Fab was initiated by diluting the
mixed Fd and LC in a buffer containing oxidised glutath-
ione. This created proper redox conditions for the refold-
ing of Fd and LC, formation of intramolecular disulfide
Diagrammatic representation of various Fab molecules along with their molecular weight in kDa Figure 2
Diagrammatic representation of various Fab molecules along with their molecular weight in kDa. S, serine; C, cysteine; L, 
spacer with sequence SGGGSGGGASG; yield corresponds to calculated amount of Fab (in mg) obtained from four litre of 
renatured material (containing 400 mg of total protein). Reactivity of proteins to HIV-1 and HIV-2 serum samples based on 
Table 2.
Yield Reactivity
HIV-1 HIV-2
Fusion protein Mol. Wt. 
(kDa)
16.2 nil high Fabenv1C CC
53.45
Fab 50.18 65.6 nil nil
19.5 nil CC Fabenv2C 54.02 high
SS Fabenv1S 53.45 22.0 low nil
S S Fabenv2S 54.02 29.5 low nil
0.5 Fabenv12CC 58.12 high high L
CC CC
12.0 Fabenv12SS 58.12 high low
L
SS S S
16.0 Fabenv12CS 58.12 high high L
S S CC
16.4 low Fabenv12SC 58.12 high
L
CC SSBMC Biotechnology 2006, 6:39 http://www.biomedcentral.com/1472-6750/6/39
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bonds, association of Fd with LC, and formation of inter-
molecular disulfide bond to form Fab. The renatured
material was dialysed to remove denaturants. This was fol-
lowed by a series of column chromatography steps to
purify monomeric Fab derivatives.
Purification of various B6Fabenv fusion proteins
A four-step protocol consisting of cation exchange, hydro-
phobic, anion exchange and gel filtration chromatogra-
phy was developed to purify various fusion proteins.
Fractions obtained at various chromatography steps were
analysed for level of purity (by SDS-PAGE) and, for pres-
ence of functional and monomeric Fab (by agglutination
assay). Fab molecules are monovalent in nature and there-
fore, can bind to RBCs but cannot cross-link RBCs to give
visible agglutination. However, these Fab-coated RBCs
can be crosslinked by MAb 9E10, which binds to c-myc
tag present at the C-terminus of all Fab molecules. There-
fore, all samples containing functional Fab molecules will
show agglutination of RBCs on addition of 9E10 and the
extent of agglutination will be directly proportional to the
amount of active, monomeric Fab in that sample. How-
ever, if a sample shows agglutination before addition of
9E10, it indicates that the Fab molecules in that sample
are not monomeric but have aggregated to become mul-
timeric. Such samples are not processed further. Purifica-
tion of B6Fab, B6Fabenv1C and B6Fabenv2C has been
described previously [6]. B6Fabenv1S and B6Fabenv2S
were purified following protocols similar to those used for
B6Fabenv13C and B6Fabenv24C, respectively. The yields
obtained for B6Fabenv proteins are shown in Fig. 2. For
purification of all the B6Fab fusion proteins containing
sequences of both env1 and env2 a modified protocol was
developed. The following section describes purification of
B6Fabenv12CS in detail.
After renaturation of B6LC and B6Fdenv12CS for assem-
bly of B6Fabenv12CS, the renatured material was dialysed
and pH of the protein solution was adjusted to 5.0, which
led to some precipitation. On analysis by SDS-PAGE, the
precipitate was found to contain mainly high molecular
weight aggregates (data not shown). The precipitate was
removed by centrifugation and filtration. The clear pro-
tein solution was loaded on SP-Sepharose column and
bound proteins were eluted with a linear gradient of NaCl.
Each fraction was analysed by SDS-PAGE and for RBC
agglutination. B6Fabenv12CS eluted between 350 to 700
mM gradient of NaCl. SDS-PAGE analysis of peak frac-
tions showed that fractions 25–37 contained a 58 kDa
band corresponding to B6Fabenv12CS protein (Fig. 3A).
In agglutination assay, fractions 35–38 showed agglutina-
tion before addition of 9E10 antibody indicating that
these fractions contained aggregates. After addition of
9E10, strong agglutination was also observed in fractions
25–34. Fractions 26–35 were pooled, neutralised to pH
Purification of B6Fabenv12CS Figure 3
Purification of B6Fabenv12CS. Renatured material (2.3 litre) 
was subjected to a series of chromatographic purification 
columns as described in methods. The fractions obtained 
through each purification step were analysed by electro-
phoresis on 0.1% SDS-10% PAG under non-reducing condi-
tions. Each lane contains sample equivalent to 10 µl of each 
fraction. The protein bands were visualised with Coomassie 
blue R-250 staining. The figure shows Coomassie blue 
stained gel of the eluted fractions from (A) SP-Sepharose, (B) 
Q-Sepharose, and (C) Sephacryl S-200 columns. Panel (A): 
Lane D, dialysed renatured material; Lane 23–37, fractions 23 
to 37 of SP-Sepharose column; Lane C, Purified B6Fab pro-
tein (control); Panel (B): Lane P1, pool of fractions from SP-
Sepharose column; Lane 22–38, fractions 22 to 38 of Q-
Sepharose column; Panel (C): Lane P2, pool of fractions from 
Q-Sepharose column; Lane 65–79, fractions 65 to 79 of 
Sephacryl S-200 gel filtration column. Filled arrows indicate 
the position of B6Fabenv12CS protein and hollow arrows of 
free B6LC. Agglutination activity of the fraction before addi-
tion of 9E10 (Ab) and after addition of 9E10 (Aa) are shown 
in boxes. '0' indicates no visible agglutination. The number 
indicates maximum dilution of sample that gave visible agglu-
tination.
(A)
D2 32 52 72 93 1 3 7 35 33 C
0 0 0 0 0 2 32 0 0 0
8 0 2 256 256 64 64 256 128 32
Ab
Aa
(C)
P2 65 66 67 69 75 78 77 76 79
0 4 0 0 0 0 0 0 0 0
256 8 16 128 64 32 16 2 64 32
Ab
Aa
(B)
P1 22 24 26 28 30 36 34 32 38
0 0 0 0 256 256 256 256 0 0
32 0 2 128 256 256 256 128 128 64
Ab
AaBMC Biotechnology 2006, 6:39 http://www.biomedcentral.com/1472-6750/6/39
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8.5 with 1M Tris solution, treated with iodoacetamide and
loaded on desalting column of Sephadex G-25 which
removed NaCl and free iodoacetamide from the sample.
The protein pool obtained from G-25 column was loaded
on 20 ml Q-Sepharose column. The Q-Sepharose column
was developed with a linear gradient of NaCl and
B6Fabenv12CS eluted between 100 to 300 mM gradient
of NaCl. SDS-PAGE of peak fractions showed that frac-
tions 24–30 contained band corresponding to
B6Fabenv12CS protein while fractions 32–38 contained
small amount of monomeric Fab (58 kDa) but large
amount of high molecular weight species (Fig. 3B). In
agglutination assay, fractions 32–40 showed agglutina-
tion before addition of 9E10 antibody indicating the pres-
ence of aggregates. After addition of 9E10, agglutination
was also observed in fractions 24–30. Fractions 24–30
were pooled and loaded on Sephacryl S-200 gel filtration
column to separate contaminating aggregated Fab mole-
cules. Fractions 66–79 showed band corresponding to
B6Fabenv12CS protein on SDS-PAGE with purity of
~90% (Fig. 3C). Fractions 70–74 containing the peak were
not loaded on the gel. In agglutination assay, fractions
63–65 showed agglutination before addition of 9E10
antibody indicating the presence of aggregates. After addi-
tion of 9E10, agglutination was observed in fractions 66–
79. Fractions 67–78 were pooled and stored. 9.2 mg of
B6Fabenv12CS protein (>90% purity) was obtained from
2.3 liter of renatured material.
B6Fabenv12SC was purified following an identical proto-
col and the elution profiles were also similar to that of
B6Fabenv12CS. 12.3 mg of B6Fabenv12SC protein was
obtained from 3.0 liter of renatured material.
B6Fabenv12CC was purified from the dialysed material
following procedures as mentioned above. However, the
amount of monomeric Fab obtained was very less. Most
of the LC and Fdenv12CC were present in free form indi-
cating that they had not associated to form Fab. 200 µg of
B6Fabenv12CC protein was obtained from 1.6 liter of
renatured material.
Characterization of purified B6 Fab and B6Fabenv fusion 
proteins
Immunoreactivity of various purified proteins was stud-
ied using two normal, seven HIV-1 positive, five HIV-2
positive and four HIV-1+2 positive serum samples follow-
ing a quantitative microtitre plate agglutination assay. The
identity of the serum samples was based on several immu-
noassays, which are able to discriminate between antibod-
ies to HIV-1 and HIV-2. In microtitre plate assay, HIV-1
positive samples showed strong agglutination with
B6Fabenv1C coated RBCs and no reactivity with
Table 2: Reactivity of various recombinant B6Fab fusion proteins to human serum samples
S.No SERUM 
SAMPLE
SOURCE OF 
SAMPLE
IDENTITY DILUTION OF SERUM GIVING END POINT OF AGGLUTINATION
B6Fab B6Fab B6Fab B6Fab B6Fab B6Fab B6Fab B6Fab B6Fab
env1S env1C env2S env2C env12SS env12SC env12CS env12CC
1. Cal 21 Calcutta HIV-1 0 1600 nd nd 0 nd nd nd 0
2. Cal 22 Calcutta HIV-1 0 1600 nd nd 0 nd nd nd 0
3. C-91 Vellore HIV-1 nd 12800 nd 0 1600 6400 12800 12800 0
4. C-92 Vellore HIV-1 nd 12800 nd 0 800 1600 12800 12800 0
5. C-93 Vellore HIV-1 nd 51200 nd 0 0 12800 51200 51200 0
6. C-95 Vellore HIV-1 nd >25600 nd 0 >25600 >25600 >25600 >25600 0
7. PRZ202-07 BBI, USA HIV-1 nd 25600 nd 0 3200 6400 >25600 25600 0
8. 266/97 Chandigarh HIV-1+2 12800 >25600 1600 3200 25600 >25600 >25600 >25600 0
9. 288/97 Chandigarh HIV-1+2 3200 25600 800 3200 6400 6400 >25600 25600 0
10. C-74 Chandigarh HIV-1+2 nd >25600 nd 25600 25600 >25600 >25600 >25600 0
11. PRZ202-
12
BBI, USA HIV-1+2 nd 1600 nd 25600 6400 25600 12800 25600 0
12. 575/97 Chandigarh HIV-2 0 0 >25600 >25600 25600 >25600 >25600 >25600 0
13. PRZ202-01 BBI, USA HIV-2 nd 0 nd >25600 >25600 >25600 >25600 >25600 0
14. PRZ202-03 BBI, USA HIV-2 nd 0 nd 12800 6400 12800 12800 12800 0
15. PRZ202-05 BBI, USA HIV-2 nd 0 nd >25600 >25600 >25600 >25600 >25600 0
16. PRZ202-09 BBI, USA HIV-2 nd 0 nd 6400 3200 6400 6400 6400 0
17. 871 Chandigarh Negative 0 0 0 0 0 0 0 0 0
18. 872 Chandigarh Negative 0 0 0 0 0 0 0 0 0
19. 9E10 MAb Control 25600 25600 12800 25600 12800 >25600 >25600 >25600 25600
Identity of samples is based on data provided by sample supplier as indicated in source of sample. Description of various fusion proteins is given in 
Fig. 2.
nd-not doneBMC Biotechnology 2006, 6:39 http://www.biomedcentral.com/1472-6750/6/39
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B6Fabenv2C or B6Fabenv2S coated RBCs (Table 2). Sim-
ilarly, HIV-2 positive samples reacted strongly with
B6Fabenv2C coated RBCs and gave no reaction with
B6Fabenv1C and B6Fabenv1S coated RBCs. Samples pos-
itive for both HIV-1 and HIV-2 showed agglutination with
both the proteins. The serum samples could be diluted to
very high degree indicating the sensitivity of detection.
B6Fab coated RBCs did not show agglutination with any
of the serum samples except for control MAb 9E10 indi-
cating the high specificity of the reagents. B6Fabenv12SS
reacted with 13 HIV positive serum samples. However,
two HIV-1 positive serum samples (Cal21 and Cal22) did
not show agglutination with this protein. These two sam-
ples also did not react with single antigen protein
B6Fabenv1S but reacted strongly with B6Fabenv1C (Table
2) indicating that cysteine residues were important for
sero-reactivity. Due to paucity of these two samples, the
double antigen molecules could not be tested. Neverthe-
less, positive reaction with B6Fabenv1C suggests the like-
lihood of the double antigen molecules also showing
positive reaction with these samples. The HIV-1+2 sam-
ples showed strong reaction with double antigen mole-
cules suggesting that both env1S and env2S sequences
were recognised by antibodies present in the serum sam-
ples.
Three of the HIV-1 positive samples (C-91, C-92, C-93)
showed very weak reactivity with B6Fabenv12SS and
B6Fabenv12SC but were strongly reactive to two other
proteins, B6Fabenv12CS and B6Fabenv12CC carrying
cysteine residues in env1 sequence. This reactivity was
similar to that of single antigen construct, B6Fabenv1C.
These results indicate that it is essential to have cysteine
residues in env1 sequence. On the other hand, HIV-2 pos-
itive samples showed strong reactivity with B6Fabenv12SS
and all other double constructs, similar to single antigen
molecule B6Fabenv2S and B6Fabenv2C, indicating that
presence of disulfide bond forming cysteine might not be
essential for immunoreactivity of env2. One HIV-1+2
sample (288/97) which showed strong reactivity to
B6Fabenv1C and weak reactivity to B6Fabenv2C was reac-
tive to all double antigen constructs and showed additive
reactivity. None of the double antigen molecules showed
agglutination with the non-HIV samples indicating their
high specificity.
Discussion
The work described here clearly demonstrates that anti-
human RBC Fab fusion proteins carrying sequences from
both envelope gp41 of HIV-1 and envelope gp36 of HIV-
2 in the same Fab molecule can be produced for use in
haemagglutination based detection of antibodies to HIV
in whole blood.
A large number of fusion proteins were designed for this
study, all of which carried an anti-human RBC Fab protein
fused to epitopes from both HIV-1 gp41 (env1) and HIV-
2 gp36 (env2) in tandem. Initially double antigen con-
struct carrying serine residues, in place of cysteine residues
present in wild type envelope sequences, was constructed.
This protein, named B6Fabenv12SS, contained Fab pro-
tein linked to env1S followed by a Gly-Ser linker and
env2S with cmyc tag at the end. Evaluation of
B6Fabenv124SS in comparison to single antigen con-
structs showed that the double antigen construct could
simultaneously detect antibodies to both HIV-1 and HIV-
2 in serum samples, with sensitivity comparable to that of
single antigen construct containing serine in envelope
(B6Fabenv1S and B6Fabenv2S). However, two HIV-1 pos-
itive samples, Cal21 and Cal22 were missed by these pro-
teins but were detected by another single antigen
construct carrying cysteine in envelope (B6Fabenv1C).
With several samples, single antigen fusion proteins carry-
ing native envelope sequence of HIV-1 gp41 (with
cysteine residues) were more sensitive than those carrying
serine residues in envelope sequence. Thus, it was impor-
tant to make double constructs with wild type sequences
of HIV-1 gp41 and HIV-2 gp36 (with cysteine residues)
for improved sensitivity. At the same time it was also
noted that cysteine residues in envelope sequences in
close vicinity to each other and to the associating LC and
Fd chain cysteines' could interfere with correct interchain
and intrachain disulfide formation.
Therefore, B6Fabenv12SS was converted into three types
of molecules containing different combination of enve-
lope sequences: (i) Fabenv12CS, containing sequence of
native gp41 of HIV-1 (env1C) followed by linker and
sequence of gp36 of HIV-2 having serine residues in place
of cysteine residues (env2S); (ii) Fabenv12SC, containing
sequence of gp41 of HIV-1 having serine residues in place
of cysteine residues (env1S) followed by linker and
sequence of native gp36 of HIV-2 (env2C), and (iii)
Fabenv12CC, containing sequence of native gp41 of HIV-
1 (env1C) followed by linker and sequence of native gp36
of HIV-2 (env2C).
The double antigen fusion proteins of B6 were purified
using a series of column chromatography procedures. On
purification, B6Fabenv12CS and B6Fabenv12SC gave
good yields that were comparable to yields of
B6Fabenv12SS and single antigen constructs of B6, indi-
cating that all the three domains, namely, Fab, env1 and
env2 were folding properly (Fig. 2). However, the yield of
B6Fabenv12CC was 20 times less compared to that of
other proteins, indicating that the molecule was not fold-
ing properly. Detailed analysis showed that the associa-
tion of Fd and LC was defective in B6Fabenv12CC. It was
thought that the spacer between the envelope sequencesBMC Biotechnology 2006, 6:39 http://www.biomedcentral.com/1472-6750/6/39
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comprising of glycine and serine residues may be very
flexible, thus bringing the cysteine residues in envelope
sequences close to each other and in close proximity to LC
and Fd causing interference in correct folding of various
domains and assembly of LC and Fd to form Fab. The flex-
ible Gly-Ser linker was replaced by other, less flexible link-
ers, comprising of proline residues. However, there was
no improvement in the assembly of LC and Fd chains and
in overall yield of proteins (data not shown).
The double antigen proteins were tested for their efficacy
in detecting anti-HIV antibodies in human serum samples
in comparison to single antigen proteins. All the double
antigen proteins showed good reactivity to HIV positive
samples with no cross-reactivity to non-HIV samples.
B6Fabenv12SS showed weaker reactivity to samples, espe-
cially to HIV-1 infected samples, as compared to other
proteins containing native envelope sequences (Table 2).
B6Fabenv12CS and B6Fabenv12SC showed very interest-
ing reactivity pattern to samples having only anti-HIV-1
antibodies. B6Fabenv12CS showed good reactivity to all
the samples, comparable to that of B6Fabenv1C. How-
ever, B6Fabenv12SC showed weaker reactivity similar to
that shown by B6Fabenv1S, emphasizing the importance
of native cysteine residues in the envelope sequence for
immunoreactivity. All proteins showed good reactivity to
HIV-2 samples. Also, HIV-1+2 samples (288/97 and PRZ
202-12) showed additive effect, with reactivity in double
antigen proteins being more than in single antigen pro-
teins (Table 2). This indicates that both the envelope anti-
gens are being recognised equally well when present in a
single protein, with no difference in sensitivity and specif-
icity compared to single antigen fusion proteins.
Conclusion
The paper describes successful designing and production
of new, bifunctional, recombinant molecules for detec-
tion of anti-HIV antibodies in blood of HIV-infected indi-
viduals. The results described above strengthen the
hypothesis that for higher sensitivity of detection, it is
essential to have native sequences of HIV-1 gp41 and HIV-
2 gp36. B6Fabenv12CC, therefore is the ideal molecule
but its yields are very low (Fig. 2). However, from this
study, B6Fabenv12CS emerges as a potential molecule for
simultaneous detection of antibodies to both HIV-1 and
HIV-2. In addition to giving good yield on purification,
B6Fabenv12CS showed good reactivity to all HIV-1 sam-
ples (Fig. 2). Also, it showed good reactivity to all HIV-2
samples inspite of having env2S sequence. This may be
due to high titre of antibodies in all the HIV-2 samples
tested in this study. It is difficult to speculate the reactivity
of this protein to low titre HIV-2 samples. It is important
to note that although HIV-2 infection is prevalent in
India, most of the cases have dual infection with very few
cases having only HIV-2 infection. Therefore,
B6Fabenv12CS should show good reactivity to most sam-
ples.
The results clearly suggest B6Fabenv12CS as the molecule
of choice for simultaneous detection of antibodies to both
HIV-1 and HIV-2, however, it needs to be evaluated for
reactivity to more samples before large-scale use. The tech-
nology described in this paper can also be used for devel-
opment of similar chimeric molecules for simultaneous,
multiplex detection of various infections, such as Hepati-
tis B, Hepatitis C and Syphilis, which are relevant to blood
transfusion.
Methods
Materials
MAb B6 was isolated by conventional hybridoma technol-
ogy in our laboratory using spleen cells from mice immu-
nised with O RhD negative human RBCs. The universal
reactivity of this antibody was established by screening
more than 1000 random blood samples. The DNA encod-
ing LC and Fd of B6 were cloned by PCR based methods
using consensus primers annealing to framework regions
of B6 (our unpublished data). Q-Sepharose fast flow, SP-
Sepharose fast flow, Sephacryl S-200 (high resolution),
Sephadex G-25 (medium) and chromatography columns
were purchased from GE Healthcare. Human serum sam-
ples were obtained from Post Graduate Institute of Medi-
cal Education and Research (PGI), Chandigarh, India,
Christian medical college (CMC), Vellore, India and Cen-
tre for Disease Control (CDC), Atlanta, USA or purchased
from Boston Biomedica Inc. (BBI), USA. These were previ-
ously collected serum samples that had been characterised
for HIV infection using immunoassays. For this study,
they were provided as coded samples and identity of the
donor was not disclosed.
Expression vector
A high copy number T7 promoter based expression vector,
pVCCD41140 [6] was used for cloning antibody
sequences. The vector utilizes E. coli host BL21(λDE3) that
carries  λ lysogen encoding T7 RNA polymerase gene
under the control of lacUV5 promoter inducible by IPTG
[8]. In this vector, DNA encoding antibody is cloned as
Nhe I-Mlu I fragment. The vector carries T7 transcription
terminator and origin of replication of filamentous phage
for making single stranded DNA. Different plasmids were
assembled using standard cloning techniques and their
sequence was confirmed by DNA sequencing (ABI Model
377). The characteristics of each plasmid are depicted in
Fig. 1.
pVCB6Fd contains DNA sequence encoding Fd of anti-
RBC monoclonal antibody, B6, as Nhe I-Mlu I fragment
followed by sequence for a 10 amino acid tag, cmyc.
pVCB6LC contains DNA sequence encoding light chain ofBMC Biotechnology 2006, 6:39 http://www.biomedcentral.com/1472-6750/6/39
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B6 (B6LC) as Nhe I-Mlu I fragment with a stop codon pre-
ceding Mlu I site.
Oligonucleotide adaptors encoding immunodominant
epitopes of gp41 of HIV-1 (amino acid 590 to 620 of HIV-
1 envelope [9] with cysteine 605 and cysteine 611
replaced by serine residues) and gp36 of HIV-2 (amino
acid 581 to 611 of HIV-2 envelope [10] with cysteine 597
and cysteine 603 replaced by serine residues) were assem-
bled from synthetic oligonucleotides and cloned into
pVCB6Fd resulting in formation of pVCB6Fdenv1S and
pVCB6Fdenv2S, respectively. The construction of plas-
mids, pVCB6Fdenv1C and pVCB6Fdenv2C which contain
sequence for env1 and env2 with cysteine residues was
carried out using similar strategy.
Construction of various plasmids to express Fd fused with 
both HIV-1 and HIV-2 antigens
DNA encoding env1 was amplified from pVCB6Fdenv1S
by PCR and cloned in vector pVCB6Fdenv2S and the
resultant recombinant was named pVCB6Fdenv12SS.
Oligonucleotides env14CC (5'-ACAGCAGTGGTGCATAT-
CAGCTTTCCTGAGCAACCCCAAATC-3') annealing to
env1S sequence and containing anticodon sequence for
the cysteine residues (underlined) and env24CC (5'-
ACCGTGGTGTGGCAGACCTGGCGGAATGCGCATC
CCCAGCTG-3') annealing to env2S sequence and con-
taining anticodon sequence for the cysteine residues
(underlined) were used simultaneously for mutagenesis
using uracil containing ssDNA template of
pVCB6Fdenv12SS and following Kunkel's method of
mutagenesis [11]. The transformants were analyzed by
restriction enzyme digestion and the sequence was con-
firmed by DNA sequencing. Mutants carrying change of
s e r i n e  t o  c y s t e i n e  i n  e n v 1  o n l y  w e r e  n a m e d
pVCB6Fdenv12CS and those with mutation of serine to
cysteine in env2 only were named pVCB6Fdenv12SC.
Double mutants carrying cysteine residues in both env1
and env2 were named pVCB6Fdenv12CC.
Expression and isolation of inclusion bodies
BL21 (λDE3) cells were transformed with various plas-
mids and grown on LB plates containing ampicillin for 16
hours at 30°C. Transformed cells from 6 plates (approxi-
mately 2000 colonies each) were scrapped and inoculated
in 1 litre superbroth containing ampicillin, and grown at
30°C with vigorous shaking. At OD600 nm of 2.5–3.0, the
culture was induced with IPTG (final concentration, 0.25
mM) and grown at 30°C. After 2 hours of induction, the
culture was chilled over ice. Cells were harvested by cen-
trifugation at 4000 × g (GSA rotor, Sorvall RC5C) for 10
min at 4°C.
Inclusion bodies were extracted by lysing the cells with
Triton X-100 and following a protocol as described earlier
[6]. The pellet containing inclusion bodies in Oak ridge
tubes was stored at -70°C till further use. The inclusion
bodies prepared were analysed on 0.1% SDS-12.5% PAG.
Assembly of Fab molecules
Inclusion Bodies isolated from one litre culture each of
B6Fd or B6Fdenv fusion protein and B6LC were solubi-
lised in 10 ml solubilisation buffer (0.1 M Tris.HCl, pH
8.0, 2 mM EDTA, 6 M Guanidine HCl. Total protein of
solubilised Fd/Fd fusion protein and LC was estimated by
Bradford method and the final protein concentration was
adjusted to 10 mg/ml. Equimolar amounts of B6LC and
B6Fd or B6Fdenv fusion proteins were taken and Dithio-
erythritol (DTE) was added to a final conc. of 10 mg/ml
and incubated at room temperature for 2 hours. After this,
LC and Fd solutions were mixed and centrifuged at 93,000
× g, for 30 minutes. The supernatant was collected and
diluted 100 fold in cold renaturation buffer (0.1 M
Tris.HCl, pH 8.0, 2 mM EDTA, 0.5 M Arginine HCl, 0.9
mM oxidised Glutathione). This material was kept undis-
turbed at 10°C for 70 hours for renaturation.
The renatured material was dialysed against three volumes
of 20 mM Tris, pH 8.0, containing 100 mM Urea. Dialysis
was done for 72 hours with 4 buffer changes. The final
dialysis was done in buffer containing 50 mM Urea. The
dialysed material was filtered through 2.3 µm and 0.4 µm
filters and then used to purify renatured, monomeric, Fab/
Fabenv fusion proteins.
Purification of Fab proteins
After renaturation, the assembled monomeric Fab fusion
protein was purified using a series of column chromato-
graphic steps. These steps were common for various
fusion proteins. Therefore, purification of only
B6Fabenv12CS (made by assembling B6LC and
B6Fdenv12CS) is described below in detail.
The pH of the dialysed and filtered solution containing
Fab fusion protein was adjusted to ~5.0 with 5% acetic
acid and the sample were kept undisturbed at 4°C for 12
hours. After centrifugation at 23,500 × g, the supernatant
was filtered through 0.4 µm filter. Using FPLC, the filtrate
(3.5 liter) was applied at a flow rate of 12 ml/min on a 50
ml SP-Sepharose column (XK 50/20) pre-equilibrated
with 20 mM acetate buffer, pH 5.0 (Buffer A). All the chro-
matography steps were carried out at 2–8°C. The column
was washed with 100 ml of Buffer A containing 100 mM
NaCl at a flow rate of 8 ml/min and the protein was eluted
with a 250 ml linear gradient of NaCl (100–600 mM) in
Buffer A. The elution was monitored at 280 nm and frac-
tions were collected. The fractions (12 ml each) were neu-
tralized immediately with 120 µl 1 M Tris solution. TheBMC Biotechnology 2006, 6:39 http://www.biomedcentral.com/1472-6750/6/39
Page 11 of 12
(page number not for citation purposes)
fractions containing the desired protein (analysed by SDS-
PAGE under non-reducing conditions and by RBC agglu-
tination assay) were pooled and pH was adjusted to ~8.5
by adding 1M Tris solution. Iodoacetamide was added to
a final concentration of 50 mM and the protein solution
was kept in a water bath at 25°C for 15 minutes. The
iodoacetamide treated sample was applied on a 325 ml
Sephadex G-25 column (XK 26/70) pre-equilibrated with
20 mM Tris Buffer, pH 8.5 (Buffer C). After loading, the
protein was eluted in Buffer C at a flow rate of 5 ml/min
with monitoring at 280 nm and collection of 12 ml frac-
tions. Based on absorbance values, fractions containing
Fab were pooled. The pool was loaded on a 20 ml Q-
Sepharose column pre-equilibrated with Buffer C. The
column was washed with 40 ml of Buffer C at a flow rate
of 4 ml/min and the protein was eluted with a 120 ml lin-
ear gradient of NaCl (0–350 mM) in Buffer C. The elution
was monitored at 280 nm and 4 ml fractions were col-
lected. The fractions were analysed by SDS-PAGE under
non-reducing conditions and by agglutination assay. The
fractions containing desired protein were pooled and the
pool was loaded on 500 ml Sephacryl S-200 gel filtration
column (XK 26/100) pre-equilibrated with 20 mM phos-
phate buffer, pH 7.0 containing 150 mM NaCl (PBS). The
column was developed with PBS at a flow rate of 1 ml/
min. The elution was monitored at 280 nm and 4 ml frac-
tions were collected and analysed. The fractions contain-
ing active, monomeric Fab fusion protein were pooled.
Agglutination assay of purification samples
60  µl of column fraction or an appropriate dilution
(including sample before column loading and flow
through obtained during loading) was taken in a 96-well
round-bottom microtitre plate (Wells 1–12). Two-fold
serial dilution were made in PBS-BSA (PBS containing
0.2% BSA) (Wells A-H). To each well, 30 µl of 2% human
RBC suspension (washed RBC pellet reconstituted v/v to
2% in PBS-BSA) was added. After mixing, the plate was
incubated at 37°C for 1 hour. Agglutination was read vis-
ually and the maximum dilution of sample that gave
agglutination (end point) was recorded. The plate was
centrifuged at 800 × g at RT for 5 minutes. The supernatant
was discarded by inversion and the pellet was suspended
in remaining buffer by vortexing. 60 µl of anti-cmyc MAb
(1:1000 dilution of 9E10 ascitic fluid in PBS-BSA) was
added per well. After mixing, the plate was incubated at
37°C for 1 hour. Agglutination was read as above. Sam-
ples, which gave agglutination only after addition of 9E10
antibody, contain active monomeric Fab/Fab fusion pro-
tein.
Quantitative plate agglutination assay to detect anti-HIV 
antibodies in serum
Human RBCs of O RhD negative blood were washed twice
with PBS-BSA. To 2% RBC suspension, purified B6Fab/
B6Fabenv fusion protein was added to a final concentra-
tion of 1 µg/ml. The contents were mixed by tapping and
inversion and incubated at 37°C for one hour with inter-
mittent mixing, to produce coated RBC suspension. Sepa-
rately, two-fold serial dilution of human sera (starting
from initial dilution of 100-fold) were made in PBS-BSA
(Wells A-H). To each well containing serum dilution, 30
µl of coated RBC suspension was added. After mixing, the
plate was incubated at 37°C for 1 hour and agglutination
was recorded.
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